Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biopharmaceutical firm PolyTherics and Celtic Pharma Development Services Bermuda, a subsidiary of Celtic Pharmaceutical Holdings have entered into a broad research collaboration agreement.
Subscribe to our email newsletter
Under the terms of the agreement, PolyTherics’s proprietary drug modification technologies will be used to enhance certain of the innovative pharmaceutical products being developed by Celtic Pharma. The companies plan to jointly develop and validate modifications of drugs submitted to the collaboration by Celtic Pharma, in order to improve their performance and assess their future development potential.
Keith Powell, CEO of PolyTherics, said: “The opportunity to collaborate with a high calibre, product-focused company such as Celtic Pharma is a significant milestone in the development of PolyTherics, and we are delighted to be working with Celtic Pharma on several of the products in their portfolio.”